Related Experiment Video
Updated: May 29, 2026
07:45
An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy
Published on: October 21, 2014
CRYAB is compromised in pathologically affected oligodendrocytes in multiple system atrophy.
Finula I Isik1,2, Jen-Hsiang T Hsiao1,2, Felicia Xaveria Suteja1
1Brain and Mind Centre, The University of Sydney, Sydney, New South Wales, Australia.
Brain Pathology (Zurich, Switzerland)
|May 28, 2026
Summary
The study found that CRYAB is hypermethylated and co-localizes with alpha-synuclein in oligodendrocytes, a key feature of multiple system atrophy.
Area of Science:
- Neuroscience
- Cell Biology
- Genetics
Background:
- Multiple system atrophy (MSA) is a neurodegenerative disorder.
- Oligodendrocytes play a crucial role in myelin sheath formation and maintenance.
- Alpha-synuclein aggregation is a hallmark of several neurodegenerative diseases, including MSA.
Purpose of the Study:
- To investigate the role of CRYAB in multiple system atrophy.
- To examine the methylation status of CRYAB in MSA oligodendrocytes.
- To determine the colocalization of CRYAB with alpha-synuclein in MSA.
Main Methods:
- Immunohistochemistry and immunofluorescence staining were used to detect CRYAB and alpha-synuclein.
- Methylation-specific PCR was employed to assess CRYAB methylation.
- Confocal microscopy was utilized for colocalization studies.
Main Results:
- CRYAB was found to be hypermethylated in oligodendrocytes from MSA patients.
- CRYAB showed significant colocalization with alpha-synuclein aggregates in MSA oligodendrocytes.
- These findings suggest a potential link between CRYAB methylation and alpha-synuclein pathology in MSA.
Conclusions:
- Hypermethylation of CRYAB may contribute to its altered expression or function in MSA.
- The colocalization of CRYAB with alpha-synuclein suggests a potential interaction or shared pathway in disease pathogenesis.
- CRYAB represents a potential therapeutic target or biomarker for multiple system atrophy.
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
01:22Lysosomal Hydrolases
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...